The FDA issues a warning letter to Johnson & Johnson subsidiary DePuy for allegedly selling more than a dozen device components not properly cleared by the watchdog agency.
Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Orthopaedics finds itself in the FDA spotlight, according to a warning letter released by the agency's Centers for Devices & Radiological Health this week.
The watchdog agency detailed more than a dozen devices or device components it said lacked proper PMA clearance or which were modified in ways that merit a new 510(k) application.
DePuy distributed the devices without seeking additional approval, believing the products to be exempt because they qualify as custom devices, according to the warning letter, filed by Steven Silverman of the CDRH's office of compliance.
"The fact that the final specifications are tailored to match a patient's anatomy does not preclude a clinical study or submission of a marketing application for the devices," Silverman wrote.
The agency urged the Warsaw, Indiana-based device maker to act swiftly to address the issues, or face penalties such as possible fines, seizure and injunction.
The inspection took place from May 10, 2011, to June 7, 2011, and also noted several quality issues, including inadequate complaint review procedures and inadequate procedures to ensure devices conform to a user's needs, according to the letter.
J&J received another warning recently for failing to report incidents where its OneTouch Ping and 2020 insulin pumps may have caused death or serious injury.
Imris says it filed for Chapter 11 bankruptcy protection, with a bailout offer from Deerfield...
Penumbra says it won 510(k) clearance from the FDA for its Ace64 intra-arterial stent.
The FDA labels as Class I CareFusion's recall of its Avea ventilators over a possibly fatal...
Small medtech companies are finding value in outsourcing their research & development functions,...